None of the Four Protocol Tools Are in Standard Treatment Guidelines
The speaker explicitly acknowledges that all four tools in the protocol — including the peptides and low-dose GLP-1 use — are not included in standard clinical guidelines. This is framed not as a safety concern but as a structural limitation of guideline development timelines. The speaker describes this as a 'gray zone' of promising, low-risk options that have not yet completed the pathway to becoming standard of care.
Larazotide Used as a Step-Up After BPC-157 and KPV Partial Response
The speaker describes a specific clinical protocol ordering: BPC-157 and KPV are used first because they are sufficient for many patients. Larazotide is reserved as the next step for patients who achieve real improvement on BPC-157 and KPV but do not reach full resolution. This sequential approach implies larazotide is a more advanced or targeted tool.
Warning: Peptide Protocols Require Root Cause Identification First
The speaker warns that peptide-based gut protocols will fail if applied before identifying and removing the underlying triggers driving inflammation. Using larazotide or BPC-157/KPV on a gut still exposed to ongoing inflammatory triggers yields only a fraction of potential benefit. The speaker frames the gut-healing phase as something that must be 'earned' by first reducing the inflammatory load.
Safety Warning: Peptide Protocols Are Not in Standard Treatment Guidelines
The speaker explicitly states that none of the four tools in the protocol — including low-dose GLP-1 agonists for inflammation, LDN, BPC-157, KPV, and larazotide — are included in standard clinical treatment guidelines. This means conventional physicians cannot recommend them in standard practice. The speaker frames this as a 'gray zone' of promising, low-risk options that have not yet completed the pathway to becoming standard of care.
Larazotide as Step-Up Agent When BPC-157/KPV Produce Incomplete Response
Larazotide is specifically positioned as a second-tier intervention for patients who achieve partial but incomplete improvement on BPC-157 and KPV. The speaker notes that applying larazotide to a gut still exposed to ongoing triggers will yield only a fraction of its potential benefit, emphasizing that root-cause identification must precede peptide use. No dosages are specified.
Four-Tool Protocol Stack for Leaky Gut: BPC-157, KPV, Larazotide, LDN, and GLP-1
The speaker describes a four-tool protocol combining two gut-targeted agents (BPC-157 and KPV) and two inflammation-targeted agents (low-dose naltrexone and low-dose GLP-1 agonists), with larazotide as a step-up option. BPC-157 and KPV address the gut lining and inflammatory gene signaling; LDN addresses neuroinflammation; GLP-1 agonists address the systemic metabolic inflammatory environment. The speaker emphasizes that none of these tools are in standard treatment guidelines.
Larazotide (Laorazzide) Targets Zonulin Pathway to Close Tight Junctions
Larazotide (referred to as 'larazzide' or 'laorazzide' in the transcript) works directly on the zonulin signaling pathway, which controls the opening and closing of intestinal tight junctions. Unlike other peptides such as BPC-157 or KPV, larazotide does not patch the gut wall from the outside but instead turns down the signal that keeps tight junctions open. It is described as a newer peptide used as a step-up when BPC-157 and KPV provide partial but incomplete improvement.
All Four Protocol Tools Are Off-Guideline — Gray Zone Clinical Practice
The speaker explicitly acknowledges that all four tools in the protocol — including GLP-1s used at low doses for inflammation — are not in any clinical treatment guideline. This is framed not as a safety concern but as a structural gap in medicine where promising, low-risk options have not yet completed the pathway to becoming standard of care. Conventional physicians are described as unable to recommend these options due to guideline constraints.
Four-Tool Protocol Stack for Leaky Gut and Chronic Inflammation
The speaker outlines a four-tool clinical protocol: (1) BPC-157 and KPV targeting the gut lining and inflammatory gene signaling, (2) larazotide targeting the zonulin/tight junction pathway, (3) low-dose naltrexone (LDN) targeting neuroinflammation, and (4) low-dose GLP-1 medications (including retatrutide) targeting the metabolic/inflammatory terrain. Two tools work at the gut itself; two work on the inflammation driving it.
Larazotide as Step-Up Therapy After BPC-157 + KPV Partial Response
The clinical protocol described positions larazotide as a second-tier intervention, used specifically when BPC-157 and KPV produce real but incomplete improvement. This sequencing is presented as clinically meaningful — larazotide is not a first-line agent but an escalation option. No dosages are provided.
Larazotide — Zonulin Pathway Inhibitor for Tight Junction Regulation
Larazotide is described as a newer peptide that works directly on the zonulin signaling pathway, which controls the opening and closing of intestinal tight junctions. Rather than patching the gut wall externally, it turns down the signal that keeps tight junctions open. The speaker distinguishes this mechanism as fundamentally different from other peptides like BPC-157 and KPV, which do not act on this pathway.
None of the Four Protocol Tools Are in Standard Clinical Guidelines
The speaker explicitly states that all four tools in the protocol — larazotide, BPC-157, KPV, and low-dose GLP-1 for inflammation — are not included in any standard clinical treatment guidelines. This is framed as the reason conventional physicians do not offer them, not because they are ineffective, but because they have not completed the pathway to becoming standard of care. This is presented as a safety-relevant context for patients considering these interventions.
Four-Tool Protocol Stack for Leaky Gut: Larazotide, BPC-157, KPV, Low-Dose GLP-1
The speaker outlines a four-tool clinical protocol for intestinal permeability: two tools targeting the gut directly (BPC-157/KPV and larazotide) and two targeting the inflammatory environment (low-dose naltrexone and low-dose GLP-1 agonist). The GLP-1 component addresses the metabolic terrain and systemic inflammation, while LDN addresses neuroinflammation. None of these four tools are described as being in standard treatment guidelines.
Larazotide Positioned as Step-Up Therapy After BPC-157 and KPV Partial Response
The speaker describes a specific clinical ordering where BPC-157 and KPV are used first for gut barrier repair, and larazotide is reserved as the next step for patients who achieve partial but incomplete improvement. This sequencing is presented as clinically meaningful, with larazotide described as a more advanced or targeted tool. No dosages are specified for any of the three peptides in this context.
Larazotide (Larazotide Acetate) Mechanism: Directly Inhibits Zonulin-Mediated Tight Junction Opening
Larazotide is described as working directly on the zonulin signaling pathway, which is the signal that instructs tight junctions in the gut lining to open. Rather than patching the gut wall externally, it turns down the signal that keeps tight junctions open, representing a mechanistically distinct approach from other gut-healing peptides. The speaker distinguishes this from BPC-157 and KPV, which do not act on this pathway.
Off-Label, Non-Guideline Status of All Four Protocol Tools — Safety and Access Context
The speaker explicitly acknowledges that all four tools in the described protocol — including low-dose GLP-1 agonists for inflammation, LDN, BPC-157, KPV, and larazotide — are not in standard clinical treatment guidelines. They are described as 'promising,' 'low risk,' and not yet having completed the pathway to becoming standard of care. Standard physicians cannot recommend them within their scope, which is why patients do not receive them through conventional medicine.
Larazotide Efficacy Dependent on Removing Underlying Triggers First
The speaker warns that larazotide will produce only a fraction of its potential benefit if applied to a gut that is still being continuously exposed to the same inflammatory triggers. The protocol requires identifying and removing root-cause drivers of inflammation before or alongside peptide use. Applying the right tool at the wrong time — before the foundation is addressed — is cited as a primary reason prior protocols failed patients.
Four-Tool Protocol Stack: BPC-157, KPV, Larazotide, LDN, and Low-Dose GLP-1
The complete described protocol for intestinal permeability involves four categories of tools used together: (1) BPC-157 and KPV targeting the gut lining and inflammatory gene signaling; (2) Larazotide targeting the zonulin/tight junction pathway; (3) Low-dose naltrexone targeting neuroinflammation; and (4) low-dose GLP-1 agonists targeting the systemic metabolic inflammatory environment. None of these uses are described as being in standard clinical guidelines.
Larazotide as Step-Up Therapy After BPC-157 and KPV Partial Response
In the described clinical protocol, BPC-157 and KPV are used first as the foundational gut-healing peptides. Larazotide is reserved as a next-step escalation for patients who achieve meaningful but incomplete improvement on BPC-157 and KPV. This sequencing is presented as clinically important for optimizing outcomes.
Larazotide (Laorazzide) — Zonulin Pathway Inhibitor for Tight Junction Regulation
Larazotide (referred to as 'larazzide' or 'laorazzide' in the transcript) is described as a newer peptide that works directly on the zonulin signaling pathway — the signal that instructs tight junctions to open. Rather than patching the gut wall externally, it turns down the signal that keeps tight junctions in an open state. This mechanism is distinguished from BPC-157 and KPV, which do not act on this pathway.
Peptide and GLP-1 Tools Require Foundation Repair First for Full Efficacy
A key mechanistic claim in the video is that peptide-based tools and GLP-1 agents cannot reach their full anti-inflammatory potential if underlying gut permeability and nervous system dysregulation are not addressed first. The sequencing principle described is: repair the foundation (gut, nutrients, dietary triggers, nervous system) first, then introduce advanced metabolic and peptide tools to amplify what is already working. This is presented as the differentiating factor between a comprehensive protocol and simply administering a single peptide.
Multi-Peptide Stack for Autoimmune Root Cause Protocol
Dr. Jones describes a comprehensive stacked protocol combining oral BPC-157 + KPV (gut lining), Thymosin Alpha-1 (immune balancing), and Larazotide (gut barrier) alongside Low Dose Naltrexone as a coordinated multi-tool approach to autoimmune remission. Each tool is assigned a specific mechanistic job within the stack, and the speaker emphasizes that none of these tools works in isolation. The protocol is presented as requiring medical supervision with ongoing lab monitoring.
Larazotide for Leaky Gut Barrier Restoration in Autoimmune Patients
Larazotide (a tight-junction regulator peptide) is included in the described multi-tool protocol specifically to address intestinal permeability. Dr. Jones positions it as working on the leaky gut barrier as a distinct mechanism from BPC-157/KPV, suggesting complementary roles within the same gut-repair stack. No dosage, route, or frequency information is provided.
Multi-Peptide Stack for Autoimmune Root-Cause Protocol
The speaker outlines a comprehensive stacked protocol combining multiple peptides alongside low-dose naltrexone, each assigned a specific mechanistic role: oral BPC-157 + KPV for gut lining, Thymosin Alpha-1 + Thymosin Beta for immune balancing, and Larazotide for barrier repair. The stack is described as sequenced and supervised, with the explicit warning that no single tool works in isolation. The protocol is positioned as complementary to — not replacing — conventional autoimmune medications. No dosages are provided for any component.
Larazotide for Leaky Gut Barrier Restoration in Autoimmune Protocols
Larazotide (a tight-junction regulator peptide) is mentioned as a specific tool targeting intestinal permeability within the practice's autoimmune protocol stack. It is described as having a distinct job — working on the leaky gut barrier — separate from BPC-157/KPV's role. No dosage, route of administration, or frequency is specified. It is presented as one of several sequenced tools rather than a standalone intervention.
Sequence-Dependent Protocol: Foundation Before Peptide/GLP-1 Intervention
The speaker emphasizes that the order of interventions is critical: foundational metabolic work (low-carb diet under 50g net carbs, therapeutic fasting, inflammation reduction) must precede the introduction of retatrutide or any peptide tools. Skipping this sequence is described as the primary reason retatrutide fails or worsens outcomes in insulin-resistant PCOS patients. This sequencing principle is presented as a core clinical protocol derived from the speaker's practice experience.
BPC-157 + KPV + Larazotide Stack for Gut-Inflammation Axis in PCOS
The speaker describes a stacked combination of BPC-157, KPV, and larazotide used together to address the gut lining and inflammation components of the PCOS metabolic protocol. Each peptide is assigned a distinct role: BPC-157 and KPV for gut lining repair, larazotide for barrier tightening. This stack is used as an adjunct to the primary metabolic intervention (retatrutide) and foundational lifestyle work, not as a standalone treatment.
Safety Warning: Retatrutide and All Protocol Medications Contraindicated in Pregnancy or Pre-Conception
The speaker issues an explicit safety warning that all medications and peptides discussed in the protocol are not recommended during pregnancy and should be stopped well ahead of any attempt to conceive, with timing individualized by a prescriber. This is flagged as non-negotiable and particularly relevant given that many women with PCOS are trying to conceive. The warning applies to the full protocol stack, not just retatrutide.
Peptide and Medication Stack for Inflammation and Gut Repair in PCOS
The speaker describes a stacking combination of BPC, KPV, and larazotide used together alongside metabolic tools (including retatrutide) to address the inflammation and gut lining components of the PCOS protocol. Low-dose naltrexone is also mentioned in this same stack context (though noted as not technically a peptide). The stack is described as targeting two of the five identified failing systems: gut microbiome disruption and chronic inflammation.
Larazotide (Laorazzide) for Leaky Gut Barrier Tightening in PCOS Protocol
Larazotide (transcribed as 'laorazzide') is described as a peptide used to tighten the leaky gut barrier as part of the gut-inflammation component of the PCOS metabolic protocol. It is positioned as a targeted support agent addressing intestinal permeability, which is identified as a driver of systemic inflammation and insulin resistance. No dosage or administration details are provided.
Prescribed Peptides with 503A Pharmacy Oversight as a Service Offering
The speaker mentions that their clinic offers prescribed peptides sourced from 503A compounding pharmacies with real medical team oversight, as an alternative pathway for patients not seeking a full functional medicine workup. This is presented as a safety and legitimacy differentiator from self-sourcing peptides via the internet or Reddit. No specific peptides, dosages, or protocols are detailed in this context.
Peptide Stack: BPC-157 + KPV + Larazotide for Gut-Inflammation Axis in PCOS
The speaker describes a specific peptide stacking combination of BPC-157, KPV, and larazotide used together to address the gut lining and inflammation components of the PCOS/insulin resistance protocol. These three agents are layered in alongside the primary metabolic tools (retatrutide) and are described as targeting the gut repair and leaky gut barrier functions within a five-system metabolic map. No dosages or frequencies are provided for any of the three.
Larazotide for Leaky Gut Barrier Tightening in PCOS Protocol
Larazotide (laorazzide as spoken) is described as a peptide used to tighten the leaky gut barrier as part of the gut/inflammation component of the PCOS metabolic protocol. It is positioned as a targeted support tool within the five-system framework, specifically addressing intestinal permeability that contributes to systemic inflammation and worsening insulin resistance. No dosage is specified.
Larazotide as a Prerequisite for Other Peptide Protocols to Work
The speaker argues that larazotide is the foundational peptide that determines whether other peptides — used for muscle, fat loss, or recovery — will be effective at all. The implication is that gut barrier dysfunction impairs the efficacy of all other stacked peptides. This is a clinical opinion claim with no supporting data or citations. No dosages are mentioned.
Leaky Gut Drives Systemic Inflammation and Insulin Resistance
The speaker claims that leaky gut — caused by stuck-open tight junctions — drives systemic inflammation, which in turn underlies insulin resistance. This is presented as a foundational problem that undermines other health and performance goals. Larazotide is positioned as the solution to this upstream driver. No dosage, study citations, or quantitative data are provided.
Leaky Gut Mechanism: Zonulin Dysregulation Opens Tight Junctions
The speaker describes the physiological basis for leaky gut: zonulin normally opens and closes intestinal tight junctions to regulate nutrient absorption. Triggers such as gluten, stress, infection, and certain medications can lock zonulin in the open position, allowing bacterial toxins and undigested food particles to enter the bloodstream. This is framed as the mechanistic rationale for why larazotide is needed. No clinical citations are provided.
Larazotide Targets Intestinal Tight Junctions via Zonulin Antagonism
Larazotide is presented as a peptide that directly acts on zonulin, the protein responsible for opening and closing intestinal tight junctions. By targeting zonulin, larazotide is claimed to close the tight junction gaps that become stuck open in leaky gut syndrome. The speaker positions this as a mechanistically unique action — directly addressing the barrier itself rather than downstream inflammation. No dosage or frequency is mentioned.
Larazotide for Gut-Brain Axis Protection: Leaky Gut to Leaky Brain Cascade
The speaker presents a mechanistic framework in which intestinal permeability ('leaky gut') driven by elevated zonulin leads to systemic inflammation that subsequently compromises the blood-brain barrier ('leaky brain'), resulting in brain fog, cognitive decline, and neuroinflammation. Larazotide is positioned as a therapeutic peptide that addresses this dual-barrier breakdown by targeting the shared upstream driver (zonulin) at the intestinal level. The claim is that fixing intestinal tight junction integrity prevents the downstream neurological consequences. No dosage information, stacking protocols, or safety warnings are provided in the transcript.
Larazotide Mechanism: Zonulin Pathway Inhibition
The proposed mechanism of larazotide centers on its antagonism of zonulin, a protein described as a 'bouncer' that regulates the opening and closing of tight junctions. When zonulin levels remain chronically elevated due to stressors such as dysbiosis, certain foods, NSAIDs, or alcohol, tight junctions stay open too long, allowing inappropriate molecular translocation and triggering systemic immune activation and inflammation. Larazotide is presented as interrupting this cascade by preventing zonulin from keeping those gates open. No in-vitro, animal, or RCT data is explicitly cited by the speaker.
Larazotide as a Tight Junction Modulator Peptide
Larazotide is described as a peptide that functions as a tight junction modulator. It works by blocking zonulin's ability to inappropriately open tight junctions in the intestinal lining and blood-brain barrier. By stabilizing intestinal tight junctions at the source, it is proposed to secondarily protect the blood-brain barrier downstream, potentially addressing brain fog, cognitive decline, and neuroinflammation. No dosage, frequency, or specific clinical trial data is cited in this presentation.
Tight Junction Disruption Caused by Gluten, Alcohol, NSAIDs, Chronic Stress, and Bacteria
The speaker identifies several triggers for tight junction breakdown, including gluten, alcohol, NSAIDs, chronic stress, undigested food, and bacteria. These are presented as the upstream causes of intestinal permeability that Larazotide is intended to address. No specific evidence tier or citations are provided for these causal claims.
Leaky Gut as the Origin of Autoimmune Symptoms, Food Sensitivities, Brain Fog, GERD, and IBS
The speaker claims that 80% of autoimmune symptoms, food sensitivities, brain fog, GERD, and IBS originate from leaky gut — a condition caused by breakdown of intestinal tight junctions. Larazotide is implicated as the therapeutic solution to this underlying mechanism. No studies or patient data are cited to support the 80% figure.
Larazotide as a Source-Level Fix for Leaky Gut vs. Downstream Inflammation
The speaker contrasts Larazotide with conventional gut supplements, arguing that most supplements only address downstream inflammation rather than the root cause. Larazotide is positioned as uniquely fixing the intestinal permeability leak at its source. No comparative clinical data or studies are cited to support this claim.
Larazotide Directly Regulates Intestinal Tight Junctions
Larazotide is described as a gut barrier peptide that directly regulates tight junctions — the cellular seals lining the intestines. The speaker claims it is the only peptide on the market with this specific mechanism of action. No dosage or frequency is mentioned in the transcript.
Peptides Used Under Medical Supervision as Part of Root Cause Functional Medicine
The speaker notes that peptides and LDN are used under medical supervision within their functional medicine program, implying these are not over-the-counter or self-administered protocols. This is the only safety-adjacent statement made regarding peptide use in the video — no contraindications, side effects, or drug interactions are discussed. The speaker positions medical oversight as a key differentiator of their clinic's approach versus self-directed protocols.
Peptides Referenced as Advanced Clinical Tools Most Specialists Are Unaware Of
The speaker frames peptides (alongside LDN) as advanced tools that 'most specialists have never heard of,' positioning them as a distinguishing feature of functional medicine practice versus conventional care. The cost of LDN ($30–$90/month from compounding pharmacies) is mentioned as context for accessibility, though no peptide pricing is given. This framing serves as both a clinical observation and a marketing claim. No safety warnings or contraindications are discussed for the peptides.
Peptides Positioned as Complementary to LDN — Each Addressing Distinct Mechanisms
The speaker explicitly distinguishes the mechanisms of peptides from those of LDN, stating that 'no peptides can do what LDN does' in targeting central nervous system inflammation via microglial pathways. This implies the peptides in the stack are viewed as complementary rather than interchangeable with LDN, each filling a different mechanistic role (gut lining, NF-κB, tight junctions vs. CNS immune modulation). No dosages are specified. This framing positions the combined protocol as superior to any single agent.
Peptide Stack Combined with LDN and GLP-1 as a Multi-Modal Anti-Inflammatory Protocol
The speaker describes layering the peptide stack (BPC-157, KPV, Larazotide) on top of Low Dose Naltrexone (LDN) and micro-dosed GLP-1 medications as a potent combined anti-inflammatory protocol. The GLP-1 micro-dosing is explicitly noted as being used for anti-inflammatory purposes rather than weight loss or diabetes management. No specific peptide dosages are given, though GLP-1 escalation from 2.5 to 10 mg over 6 months is mentioned in a patient case. This is presented as the clinic's advanced multi-system approach.
Peptides Described as Turning Off Inflammation at a Genetic Level
The speaker makes a broad claim early in the video that peptides can 'turn off inflammation at a genetic level,' framing this as a distinguishing feature of the clinical tools used in their practice. This claim is most directly supported by the subsequent description of KPV's NF-κB inhibition mechanism, which operates at the level of gene transcription. No specific dosages or study citations are provided for this overarching claim. It is presented as a key differentiator from standard dietary interventions.
Peptide Stack (BPC-157 + KPV + Larazotide) for Gut and Systemic Inflammation
The speaker describes a three-peptide clinical stack combining BPC-157, KPV, and Larazotide as a coordinated approach to gut and systemic inflammation. Each peptide is said to address a distinct mechanism: BPC-157 heals the gut lining and boosts antioxidants, KPV blocks NF-κB inflammatory gene activation, and Larazotide repairs tight junctions and the zonulin pathway. No individual or combined dosages are specified. This stack is presented as a standard clinical protocol in the speaker's functional medicine clinic.
Larazotide (Laorazzide) Targets Tight Junctions to Heal Leaky Gut
Larazotide (transcribed as 'laorazzide') is described as directly targeting tight junctions in the gut lining — the cellular seals that, when loosened, produce the condition known as leaky gut. The speaker specifically references the zonulin pathway as a key mechanism, noting that zonulin is a protein that becomes dysfunctional in leaky gut and that larazotide addresses intestinal permeability at the mechanistic level. No dosage is mentioned. Presented as a clinical tool.
Integrated autoimmune protocol: root cause + peptides + medical oversight
Dr. Jones outlines a three-pillar protocol for autoimmune conditions: (1) root cause functional medicine addressing gut, inflammation, nutrients, diet, and nervous system; (2) advanced tools including low-dose naltrexone, anti-inflammatory diet, and therapeutic peptides (BPC-157, KPV, Larazotide, Thymosin Alpha-1, GLP-1s); (3) medical oversight. He emphasizes that most programs only offer one or two of these pieces, and all three are needed for success.
BPC-157, KPV, and Larazotide for gut repair and systemic inflammation in autoimmune patients
As part of a layered functional medicine protocol for autoimmune conditions, Dr. Jones recommends peptides BPC-157 ('BPC57' as spoken), KPV, and Larazotide specifically for gut repair and reducing systemic inflammation. These are positioned as advanced tools used after foundational interventions (gut health, anti-inflammatory diet, nutrient repletion) are in place. No specific dosages are provided.